Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Delta Variant

<< Previous

Bullboard Posts

Next >>

Comment by 99942Apophison Jun 15, 2021 8:11am

151 Views

Post# 33387048

RE:RE:RE:Delta Variant

Thanks CancerSlayer, still would be nice if at the AGM Shawn will discuss progress or start date for animal & human trials for vaccine if known.

CancerSlayer wrote

CancerSlayer wrote:

99942Apophis wrote: I am by far no expert! However this Delta Variant appears to me as the deadliest so if a biopharmaceutical company could prove their vaccine would be highly effective against this and any other possible variants it would make world news instantly. Perhaps during the AGM someone could pose this question if Theralase Covid-19 vaccine would be able to protect against this latest Variant to emerge or even against ones still to emerge! Any thoughts on this would be appreciated, thanks.

Hi Apophis....good question, but it's too early to postulate about vaccine potential at this early stage. However, in using TLD-1433 +/- PDT as a therapeutic, one can more clearly see potential based on Dr. Coombs' preclinical work. I hope TLT eventually pursues this further.

As for the Delta variant, a recent study from Public Health England showed that the Pfizer vaccine was 88% effective in preventing symptomatic disease due to Delta...not bad at all considering the influenza vaccine is typically 40-50% effective. The RNA technology used in making the Pfizer vaccine appears to provide a big edge.